CSL is a global biotechnology company headquartered in Melbourne, Australia, operating through CSL Behring, CSL Seqirus, and CSL Vifor. The company specializes in plasma-derived biotherapies for rare and serious diseases including bleeding disorders and immunodeficiencies, vaccines, and iron deficiency treatments, but operates as an integrated developer/manufacturer for its own products rather than as a CDMO offering contract services to external clients.
Plasma fractionation, biotherapeutics for rare diseases, vaccines, recombinant protein technology, gene therapy (HEMGENIX)
2 sites worldwide
Involvement in 9 clinical trials
No reviews available yet.
No documents available.